Specialty Generics Market Report 2026

The specialty generics market size has grown rapidly in recent years. It will grow from $107.14 billion in 2025 to $122.7 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to rising prevalence of autoimmune diseases, patent expirations of branded specialty drugs, increasing investment in healthcare infrastructure, growth of hospital and retail pharmacy networks, early adoption of biosimilars in key markets.

The specialty generics market size is expected to see rapid growth in the next few years. It will grow to $214.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to expansion of specialty generics portfolio, advancements in biologics manufacturing technology, increasing healthcare expenditure, growing demand for personalized therapies, rising collaborations between pharma companies and CDMOs. Major trends in the forecast period include growth in biologics and biosimilars adoption, expansion of specialty pharmacy services, personalized medicine integration, increasing regulatory compliance complexity, rise in chronic disease treatment demand.

The rising prevalence of chronic diseases is expected to drive demand in the specialty generics market. Chronic diseases are long-term conditions that often cannot be completely cured but can be managed or controlled in many cases. Changes in lifestyle, dietary habits, and poor weight management contribute significantly to the increasing incidence of chronic conditions, while certain long-standing chronic infections can elevate the risk of cancer. As exposure to these diseases continues to grow, the need for specialty generics to manage complex and long-term conditions is increasing. For instance, in March 2025, according to GOV.UK, a UK-based non-profit government organization, GP-recorded type 2 diabetes prevalence among adults aged 17 and over in England reached 7% in March 2024, up from 6.8% in March 2023. Therefore, the surge in chronic diseases is fueling the growth of the specialty generics market.

Major companies operating in the specialty generic market are obtaining approvals for drugs such as Lisdexamfetamine Dimesylate to meet the growing need for effective medications. Approval in specialty generics refers to the regulatory authorization granted to pharmaceutical products that demonstrate bioequivalence and therapeutic equivalence to branded specialty drugs, which are typically used to treat complex or rare medical conditions after patent expiration. For instance, in August 2023, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, received FDA approval for its Lisdexamfetamine Dimesylate Capsules under the SpecGx LLC Specialty Generics segment for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine dimesylate is a specialty generic and a federally controlled substance (CII) used in the treatment of ADHD and other indications.

In March 2025, Mallinckrodt Pharmaceuticals, an Ireland-based provider of specialty pharmaceuticals, specialty generics, sterile injectables, and active pharmaceutical ingredients (APIs), merged with Endo Inc. for an enterprise value of approximately US$6.7 billion. Through this merger, the companies aim to combine their specialty generics and sterile injectables capabilities, generating operational synergies across manufacturing, regulatory compliance, and research and development. The transaction also includes plans for a future spin-off of the combined generics and sterile injectables business as a standalone entity. This merger highlights the ongoing consolidation within the specialty generics market and reflects a strategic focus on high-barrier, complex generics and sterile injectable products. Endo Inc. is a US-based provider of generics and sterile injectable products.

Major companies operating in the specialty generics market are Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

North America was the largest region in the specialty generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the specialty generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the specialty generics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and biologics components, thereby impacting production costs. The injectables and oral segments are particularly affected, with North America and Europe facing higher regulatory and cost pressures. While tariffs may raise prices, they also encourage domestic manufacturing investments and local sourcing strategies, fostering innovation and supply chain resilience in the specialty generics sector.

The specialty generics market research report is one of a series of new reports that provides specialty generics market statistics, including specialty generics industry global market size, regional shares, competitors with a specialty generics market share, detailed specialty generics market segments, market trends and opportunities, and any further data you may need to thrive in the specialty generics industry. This specialty generics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Specialty generics refer to generic versions of complex, high-cost, or high-touch medications that typically require enhanced patient support and specialized handling. These drugs often involve complex formulations, manufacturing processes, or delivery mechanisms and require substantial service participation for effective management. Specialty generics also include biologics and biosimilars, which follow distinct regulatory approval pathways. Most specialty medications are used in the treatment of conditions such as cancer, rheumatoid arthritis, multiple sclerosis, and other chronic or rare diseases.

The main routes of administration for specialty generics include injectables, oral, and other routes. Injectable specialty generics are widely used and can be administered through intravenous, subcutaneous, intradermal, intraperitoneal, intramuscular, and other methods to treat a broad range of medical conditions, from oncology to autoimmune disorders. Drug injections typically involve the use of a hollow hypodermic needle to deliver the medication directly into the bloodstream or targeted tissue. Specialty generics are commonly indicated for oncology, autoimmune diseases, infectious diseases, and other therapeutic areas, and they are distributed through retail pharmacies, specialty pharmacies, and hospital pharmacies.

The specialty generics market consists of sales of biologics and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.